Press release content from Business Wire. The AP news staff was not involved in its creation.
LianBio Appoints Yizhe Wang, Ph.D., as Chief Executive Officer
May 10, 2021 GMT
SHANGHAI & PRINCETON, N.J. (BUSINESS WIRE) May 10, 2021
LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced Yizhe Wang, Ph.D., has been named Chief Executive Officer and appointed to the Board of Directors, effective May 17, 2021.
“Yizhe is a strategic leader with decades of experience developing, launching and managing the product lifecycle of transformative drugs in China, the U.S. and Europe,” said Konstantin Poukalov, Managing Director, Perceptive Advisors and Executive Chairman, LianBio. “With his proven leadership guiding late-stage assets to market in China, LianBio is well positioned for our next phase of growth as we continue to advance our pipeline and partner with leading global biopharmaceuti
May 10, 2021 10:50am Yizhe Wang arrives two months after LianBio struck its latest partnerships and added Yi Larson as chief financial officer to the team. (Freeman Zhou / Unsplash)
As LianBio strikes more deals to bring new drugs to China, the company is installing a new CEO: Yizhe Wang, Ph.D., who will arrive next Monday after leading the team that brought Eli Lilly’s COVID-19 antibody, bamlanivimab, to an emergency nod. Wang fills a vacuum left by LianBio’s founding CEO Bing Li, who departed quietly earlier this year.
Wang led global brand development at Lilly’s oncology unit and in 2020, also served as the global platform lead for anti-COVID therapy. Before that, he led Lilly’s biomedicines and oncology units in China and held various roles at GlaxoSmithKline over a 15-year tenure.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III
February 8, 2021 GMT
SEATTLE & NEW YORK (BUSINESS WIRE) Feb 8, 2021
Nautilus Biotechnology, Inc. (“Nautilus Biotechnology” or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, and Arya Sciences Acquisition Corp III (Nasdaq: ARYA) (“Arya III”), a special purpose acquisition company or
SPAC, sponsored by Perceptive Advisors, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, Arya III will redomicile as a Delaware corporation, be renamed Nautilus Biotechnology, Inc. and its common stock is expected to be listed on Nasdaq under the ticker symbol “NAUT” (the “Combined Company”).